http://www.medpagetoday.com
NEW ORLEANS -- Half of patients with myelofibrosis had major clinical responses to an investigational inhibitor of Janus activated kinase (JAK), according to data from the largest-ever trial of patients with the incurable bone marrow disease.
I am grateful for the effort that you are putting towards helping us with myelofibrosis. Please feel free to contact me anytime you are looking for someone to experiment to help the cause. Thank You 64/m/toronto
dotonthewall 1 month ago